Hepatitis D Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEssentia, REPLICor, Soma

Hepatitis D Pipeline constitutes 6+ key companies continuously working towards developing 6+ Hepatitis D treatment therapies, analyzes DelveInsight.

Hepatitis D Overview:

Hepatitis D, or "delta hepatitis," is a liver infection caused by the hepatitis D virus (HDV). It only occurs in individuals who are also infected with the hepatitis B virus. The virus is transmitted when blood or other bodily fluids from an infected person enter the body of someone who is not infected. Hepatitis D can manifest as an acute, short-term infection or progress to a long-term, chronic condition. It can lead to severe symptoms and significant illness, potentially causing permanent liver damage and even death. People can be infected with both hepatitis B and D simultaneously (coinfection) or contract hepatitis D after being infected with hepatitis B (superinfection). While there is no specific vaccine for hepatitis D, vaccination against hepatitis B also provides protection against hepatitis D infection.

Request for a detailed insights report on Hepatitis D pipeline insights @ https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Hepatitis D Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hepatitis D Therapeutics Market.

Key Takeaways from the Hepatitis D Pipeline Report

DelveInsight's Hepatitis D pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Hepatitis D treatment.
In October 2024, Bluejay Therapeutics announces upcoming data presentations on Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at the 2024 American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®.
In September 2023, Eiger BioPharmaceuticals announced the discontinuation of its Phase III LIMT-2 study of peginterferon lambda in patients with chronic hepatitis D. This decision was made following a recommendation from the Data Safety Monitoring Board (DSMB) after their routine safety review.
Key Hepatitis D companies such as Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEssentia, REPLICor, SomaGenics, Vir Biotechnology, VLP Biotech, and others are evaluating new drugs for Hepatitis D to improve the treatment landscape.
Promising Hepatitis D pipeline therapies in various stages of development include Lonafarnib, JNJ 73763989, and others.

Hepatitis D Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Hepatitis D Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hepatitis D market.

Download our free sample page report on Hepatitis D pipeline insights @ https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hepatitis D Emerging Drugs

Lonafarnib: Eiger Biopharmaceuticals
JNJ 73763989: Arrowhead Pharmaceuticals

Hepatitis D Companies

Around six key companies are developing therapies for Hepatitis D. Among them, Eiger Biopharmaceuticals has drug candidates for Hepatitis D in the most advanced stage, specifically phase III.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Hepatitis D Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Hepatitis D Therapies and Key Companies: Hepatitis D Clinical Trials and advancements @ https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hepatitis D Pipeline Therapeutic Assessment
• Hepatitis D Assessment by Product Type
• Hepatitis D By Stage
• Hepatitis D Assessment by Route of Administration
• Hepatitis D Assessment by Molecule Type

Download Hepatitis D Sample report to know in detail about the Hepatitis D treatment market @ Hepatitis D Therapeutic Assessment @ https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Hepatitis D Current Treatment Patterns
4. Hepatitis D - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hepatitis D Late-Stage Products (Phase-III)
7. Hepatitis D Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hepatitis D Discontinued Products
13. Hepatitis D Product Profiles
14. Hepatitis D Key Companies
15. Hepatitis D Key Products
16. Dormant and Discontinued Products
17. Hepatitis D Unmet Needs
18. Hepatitis D Future Perspectives
19. Hepatitis D Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Hepatitis D Pipeline Reports Offerings: https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.